The Rationale for Druggability of CCDC6-tyrosine Kinase Fusions in Lung Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2018 Feb 20

PMID 29455670

Citations 13

Authors

Aniello Cerrato

Roberta Visconti

Angela Celetti

Affiliations

Soon will be listed here.

Abstract

Gene fusions occur in up to 17% of solid tumours. Oncogenic kinases are often involved in such fusions. In lung cancer, almost 30% of patients carrying an activated oncogene show the fusion of a tyrosine kinase to an heterologous gene. Several genes are partner in the fusion with the three kinases ALK, ROS1 and RET in lung. The impaired function of the partner gene, in combination with the activation of the kinase, may alter the cell signaling and promote the cancer cell addiction to the oncogene. Moreover, the gene that is partner in the fusion to the kinase may affect the response to therapeutics and/or promote resistance in the cancer cells. Few genes are recurrent partners in tyrosine kinase fusions in lung cancer, including CCDC6, a recurrent partner in ROS1 and RET fusions, that can be selected as possible target for new strategies of combined therapy including TKi.

Citing Articles

Activity of afatinib in patients with NSCLC harboring novel uncommon mutations with or without co-mutations: a case report.

Christopoulos P, Herster F, Hoffknecht P, Falk M, Tiemann M, Kopp H Front Oncol. 2024; 14:1347742.

PMID: 38769948 PMC: 11103604. DOI: 10.3389/fonc.2024.1347742.

Abnormal phase separation of biomacromolecules in human diseases.

Zhang S, Pei G, Li B, Li P, Lin Y Acta Biochim Biophys Sin (Shanghai). 2023; 55(7):1133-1152.

PMID: 37475546 PMC: 10423695. DOI: 10.3724/abbs.2023139.

A phylogenetic profiling approach identifies novel ciliogenesis genes in Drosophila and C. elegans.

Dobbelaere J, Su T, Erdi B, Schleiffer A, Dammermann A EMBO J. 2023; 42(16):e113616.

PMID: 37317646 PMC: 10425847. DOI: 10.15252/embj.2023113616.

Kinase regulation by liquid-liquid phase separation.

Lopez-Palacios T, Andersen J Trends Cell Biol. 2022; 33(8):649-666.

PMID: 36528418 PMC: 10267292. DOI: 10.1016/j.tcb.2022.11.009.

Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.

Liang Z, He Y, Hu X Int J Mol Sci. 2022; 23(18).

PMID: 36142538 PMC: 9501315. DOI: 10.3390/ijms231810617.

References

Castellone M, Santoro M . Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin North Am. 2008; 37(2):363-74, viii. DOI: 10.1016/j.ecl.2008.02.006. View

Camidge D, Bang Y, Kwak E, Iafrate A, Varella-Garcia M, Fox S . Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13(10):1011-9. PMC: 3936578. DOI: 10.1016/S1470-2045(12)70344-3. View

Chmielecki J, Peifer M, Jia P, Socci N, Hutchinson K, Viale A . Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res. 2010; 38(20):6985-96. PMC: 2978357. DOI: 10.1093/nar/gkq579. View

Lee S, Lee J, Ahn M, Kim D, Sun J, Keam B . Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2016; 28(2):292-297. DOI: 10.1093/annonc/mdw559. View

Bergethon K, Shaw A, Ou S, Katayama R, Lovly C, McDonald N . ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30(8):863-70. PMC: 3295572. DOI: 10.1200/JCO.2011.35.6345. View

Visconti R, Morra F, Guggino G, Celetti A . The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. Int J Mol Sci. 2017; 18(7). PMC: 5535867. DOI: 10.3390/ijms18071374. View

Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan A . Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015; 7:129. PMC: 4683719. DOI: 10.1186/s13073-015-0252-1. View

Birchmeier C, Sharma S, Wigler M . Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A. 1987; 84(24):9270-4. PMC: 299735. DOI: 10.1073/pnas.84.24.9270. View

Knostman K, Venkateswaran A, Zimmerman B, Capen C, Jhiang S . Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression. Thyroid. 2007; 17(12):1181-8. DOI: 10.1089/thy.2007.0224. View

10.

Wang Y, Ding X, Wang S, Moser C, Shaleh H, Mohamed E . Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett. 2016; 380(1):163-73. PMC: 5119950. DOI: 10.1016/j.canlet.2016.05.017. View

11.

Drizou M, Kotteas E, Syrigos N . Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it. Clin Transl Oncol. 2017; 19(6):658-666. DOI: 10.1007/s12094-016-1605-y. View

12.

Ou S, Chalmers Z, Azada M, Ross J, Stephens P, Ali S . Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer. 2015; 88(3):352-4. DOI: 10.1016/j.lungcan.2015.03.014. View

13.

Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H . ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014; 84(2):121-6. DOI: 10.1016/j.lungcan.2014.02.007. View

14.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

15.

Murray P, Lax I, Reshetnyak A, Ligon G, Lillquist J, Natoli Jr E . Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci Signal. 2015; 8(360):ra6. DOI: 10.1126/scisignal.2005916. View

16.

Birch A, Arcand S, Oros K, Rahimi K, Watters A, Provencher D . Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One. 2011; 6(12):e28250. PMC: 3232202. DOI: 10.1371/journal.pone.0028250. View

17.

Drechsler M, Hildebrandt B, Kundgen A, Germing U, Royer-Pokora B . Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol. 2007; 86(5):353-4. DOI: 10.1007/s00277-006-0247-5. View

18.

Davies K, Doebele R . Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013; 19(15):4040-5. PMC: 3732549. DOI: 10.1158/1078-0432.CCR-12-2851. View

19.

Morris S, Kirstein M, Valentine M, Dittmer K, Shapiro D, Saltman D . Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263(5151):1281-4. DOI: 10.1126/science.8122112. View

20.

Vaishnavi A, Schubert L, Rix U, Marek L, Le A, Keysar S . EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017; 77(13):3551-3563. PMC: 5516930. DOI: 10.1158/0008-5472.CAN-17-0109. View